Astellas Rejigs R&D Focus Areas As It Withdraws From Mitochondria R&D

Ex-Mitobridge Asset Dropped

 
• By Lisa Takagi
  
Astellas decided to terminate its mitochondrial study and to remove the category from its primary focus.
Astellas mitochondrial R&D decision removes category as primary focus • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip